Department of Biochemistry, Lapeyronie Hospital, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.
Support Care Cancer. 2012 Dec;20(12):3129-35. doi: 10.1007/s00520-012-1444-5. Epub 2012 Mar 28.
Inflammatory, angiogenic and oxidative stress markers have been explored in head and neck squamous cell carcinoma (HNSCC) patients before and during radiochemotherapy. Furthermore, the effects of an oral supplementation containing amino acids, ω-3 fatty acids, ribonucleic acids, vitamins, and antioxidants on biological markers and acute toxicities were investigated.
Thirty-one patients with non-metastatic stage III or IV HNSCC treated with concomitant radiochemotherapy were recruited. A nutritional support (Oral Impact) was given during 5 days before each cycle of chemotherapy. Biological samples were collected at baseline, after 5 days of oral supplementation and before the last cycle of chemotherapy. Acute phase proteins levels, proteomic cytokines determination and urinary isoprostanes levels were used as inflammatory and oxidative stress biomarkers. Toxicities were followed up during radiochemotherapy.
At baseline, median levels of inflammatory (CRP 9.8 mg/l [0.8-130.1], IL-6 4.2 pg/ml [0.7-126.5]), pro-angiogenic (VEGF 229.5 pg/ml [13.1-595.9]) and pro-oxidative stress (urinary isoprostanes 118 pmol/mmol creatinine [51-299]) markers were increased. Decrease in CRP (p = 0.002) and α-1 acid glycoprotein (p = 0.020) levels were observed after 5 days of oral supplementation. During radiochemotherapy, no significant variation of inflammatory markers was reported, and a low incidence of severe acute mucositis was noted.
Stage III or IV HNSCC patients are characterised by a pro-inflammatory, pro-angiogenic and pro-oxidative status. Nutritional support could improve this inflammatory state and could prevent severe acute mucositis.
在头颈部鳞状细胞癌(HNSCC)患者接受放化疗前后,研究了炎症、血管生成和氧化应激标志物。此外,还研究了一种含有氨基酸、ω-3 脂肪酸、核糖核酸、维生素和抗氧化剂的口服补充剂对生物标志物和急性毒性的影响。
招募了 31 名接受同期放化疗的非转移性 III 或 IV 期 HNSCC 患者。在每个化疗周期前 5 天给予营养支持(口服冲击)。在基线、口服补充 5 天后和最后一个化疗周期前采集生物样本。急性蛋白水平、蛋白质组细胞因子测定和尿异前列烷水平被用作炎症和氧化应激生物标志物。在放化疗期间监测毒性。
基线时,炎症标志物(CRP 9.8mg/L[0.8-130.1],IL-6 4.2pg/ml[0.7-126.5])、促血管生成标志物(VEGF 229.5pg/ml[13.1-595.9])和促氧化应激标志物(尿异前列烷 118pmol/mmol 肌酐[51-299])的中位数水平升高。口服补充 5 天后,CRP(p=0.002)和α-1 酸性糖蛋白(p=0.020)水平下降。在放化疗期间,炎症标志物无显著变化,且严重急性黏膜炎发生率较低。
III 或 IV 期 HNSCC 患者表现出促炎、促血管生成和促氧化状态。营养支持可改善这种炎症状态,并可预防严重的急性黏膜炎。